Detail akcie Guerbet SA online

Business Summary: Guerbet SA is a France-based pharmaceutical group specialized in the manufacture and marketing of medical imaging contrast agents destined for diagnostic purposes. It produces medical imaging contrast products for x-ray imaging, magnetic resonance imaging (MRI), ultrasound imaging and for nuclear medicine. The contrast agents are used in the diagnosis of cardio-vascular, inflammatory and neuro-degenerative disorders. The Company’s portfolio of products comprises brands, such as Xenetix, Hexabrix, Optiray, Oxilan, Telebrix, Lipiodol, Dotarem, Endorem, Artirem, Lumirem, and Lipiodol, among others. Guerbet SA is also active in the fine chemicals industry through its Simafex subsidiary. The Company operates through its subsidiaries, including Simafex, Medex, SCI KALB, Guerbet LLC, Guerbet Asie Pacifique and Guerbet GmbH, among others.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Guerbet SA revenues decreased 6% to EUR786.4M. Net loss applicable to common stockholders totaled EUR108.3M vs. income of EUR16.1M. Revenues reflect X-rays segment decrease of 11% to EUR427.8M, MRI segment decrease of 4% to EUR252.4M. Net loss reflects Impairment of Intangibles Excl Goodwill increase from EUR74K (income) to EUR25.8M (expense).